ArticleAnnals of neurology2026

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study.

Thomas Frisell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.